Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?

Journal of Clinical Virology

Volumn 56, Issue 2, 2013, Pages 146-149

  Dumortier, Jérôme ^a   Guillaud, Olivier ^a   Gagnieu, Marie Claude ^a   Janbon, Bénédicte ^b   Juillard, Laurent ^a   Morelon, Emmanuel ^a   Leroy, Vincent ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

^c INSERM   (France)

Author keywords

Haemodialysis; Hepatitis C; Interferon; Protease inhibitor; Ribavirin; Treatment

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CASE REPORT; CAUCASIAN; CENTRIFUGATION; CHRONIC KIDNEY FAILURE; COLUMN CHROMATOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELASTOGRAPHY; FEASIBILITY STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; FRANCE; GENOTYPE; GRAFT FAILURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VIRUS IDENTIFICATION; VIRUS LOAD;

ADULT; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OLIGOPEPTIDES; RENAL DIALYSIS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872403051     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.10.009     Document Type: Article

References (29)

1. Hardy N.M., Sandroni S., Danielson S., Wilson W.J. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992, 38:44-48.
2. Mitwalli A., al-Mohaya S., al Wakeel J., el Gamal H., Rotimi V., al-Zeben A., et al. Hepatitis C in chronic renal failure patients. Am J Nephrol 1992, 12:288-291.
3. Mathurin P., Mouquet C., Poynard T., Sylla C., Benalia H., Fretz C., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999, 29:257-263.
4. Nakayama E., Akiba T., Marumo F., Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000, 11:1896-1902.
5. Rahnavardi M., Hosseini Moghaddam S.M., Alavian S.M. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol 2008, 28:628-640.
6. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
7. Vachon M.L., Dieterich D.T. The era of direct-acting antivirals has begun: the beginning of the end for HCV?. Semin Liver Dis 2011, 31:399-409.
8. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
9. Leroy V., Serfaty L., Bourliere M., Bronowicki J.P., Delasalle P., Pariente A., et al. Protease inhibitor-based triple therapy in chronic hepatitis C: Guidelines by the French association for the study of the Liver. Liver Int 2012, 32:1477-1492.
10. Quaranta S., Woloch C., Paccou A., Giocanti M., Solas C., Lacarelle B. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. Ther Drug Monit 2009, 31:695-702.
11. Chakilam A. 6th international workshop on clinical pharmacology of hepatitis therapy 2011.
12. Dumortier J., Ducos E., Scoazec J.Y., Chevallier P., Boillot O., Gagnieu M.C. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat 2006, 13:538-543.
13. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van Vliet A., van de Wetering de Rooij J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131:997-1002.
14. Pereira B.J., Levey A.S., Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997, 51:981-999.
15. Pipili C., Ilonidis G., Cholongitas E., Hepatitis C. virus and kidney: a strong association with different clinical aspects. Liver Int 2011, 31:1071-1080.
16. Strader D.B., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
17. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008, 109:S1-S99.
18. Kamar N., Toupance O., Buchler M., Sandres-Saune K., Izopet J., Durand D., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003, 14:2092-2098.
19. Nomura H., Sou S., Tanimoto H., Nagahama T., Kimura Y., Hayashi J., et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004, 39:1213-1219.
20. Fabrizi F., Dixit V., Martin P., Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2011, 18:e263-e269.
21. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
22. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
23. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
24. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
25. Perry C.M. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012, 72:619-641.
26. Yamada I., Suzuki F., Kamiya N., Aoki K., Sakurai Y., Kano M., et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat 2012, 19:e112-e119.
27. Marcellin P., Forns X., Goeser T., Ferenci P., Nevens F., Carosi G., et al. Telaprevir is effective given every 8 or 12hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011, 140. 459-68 e1; quiz e14.
28. Chayama K., Takahashi S., Toyota J., Karino Y., Ikeda K., Ishikawa H., et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55:742-748.
29. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366:216-224.